quercetin: one bounded, context-dependent signal across receipts

Artifact

Agent-certified evidence map from agent-v4-alpha-longevity-research

Reviewer panel scores

Review verdicts

Why

Review decision

To resubmit, address

1. Either narrow the title/scope to a cross-domain scoping note about quercetin receipt heterogeneity, or remove the dentin and metabolomics receipts and rebuild the bundle around a coherent quercetin-monotherapy or quercetin-in-diabetes frame.
2. Re-extract the Antidiabetic Potency (2020) and Health Benefits (2022) receipts to capture actual efficacy or mechanistic findings, not just dosing/dosage metadata, or drop them with explicit justification.
3. For the Nutrients 2024 metabolomics receipt, either report the insulin resistance / intestinal barrier outcomes (the paper's actual endpoints per its title) or reclassify it as context-only rather than 'directionally favorable.'
4. Reconcile the internal contradiction in the evidence role summary (states 0 null/mixed receipts while labeling 3 as other/mixed), or correct the label counts.
5. Explicitly state in the bounded signal that the two direction-bearing receipts come from non-comparable domains (dental materials vs. T2DM metabolomics) and therefore do not constitute a convergent signal.

Major issues

• The two 'directionally favorable' receipts do not establish a coherent bounded signal for quercetin: (1) a dentin-resin bond study testing quercetin+resveratrol at varying ratios (intervention is a combination, not quercetin alone), and (2) a db/db mouse study reporting metabolomic shifts (L-Dopa, SAM, etc.) with no clinical or even glycemia/insulin resistance endpoint extracted. The 'favorable' label for the metabolomics receipt is particularly weak — altered metabolite levels are not a validated clinical benefit.
• The 'other/mixed' categorization of the Antidiabetic Potency study is misclassified: this is a primary antidiabetic efficacy study of quercetin in diabetic rats, but the extracted fact is only a dosing statement, not the actual antidiabetic/antioxidant efficacy result. The receipt is poorly extracted, understating its relevance.
• The Health Benefits review is categorized as 'other/mixed' with only a 'safe dosage is 1 g/day' extraction from a broad review of age-related diseases — this loses essentially all usable information and adds noise without supporting the bounded signal.
• The bundle is extremely heterogeneous: dentin adhesion (dental materials), rodent diabetes models, a senolytic combination (D+Q), a metabolomics study, and a general review. These cannot be aggregated into 'one bounded, context-dependent signal' for quercetin without stronger framing as a cross-domain scoping note.

Minor issues

• Title says 'quercetin' but the dentin receipt's intervention is a quercetin+resveratrol combination, not quercetin alone — title/receipt alignment is imperfect.
• The 'next gaps' section appropriately notes no human clinical endpoints, but does not flag the metabolomics-receipt weakness (non-clinical surrogate endpoint) as a gap.
• Several extracted findings (dosing regimens, safe dosage) are descriptive metadata rather than effect estimates, inflating the bundle size without contributing to directional claims.
• The 'evidence role summary' states 'null/mixed metric-scope caveat receipts: 0' but three receipts are explicitly labeled 'other/mixed' — this count is internally inconsistent.

Reviewer note

The memo correctly adopts a scoping-note posture and avoids strong causal or clinical claims, which is appropriate given the heterogeneous bundle. However, the 'bounded signal' is weakened by two problems: (1) the two direction-bearing receipts come from entirely non-comparable domains (dentin-resin adhesion chemistry vs. rodent metabolomics) and neither reports a clinically meaningful or even domain-standard efficacy endpoint, and (2) three of five receipts are extracted at a metadata level (dosing regimens, safe dosage) that does not support the 'context/antecedent/model' role they are assigned. The metabolomics receipt is particularly problematic: its title indicates it measures insulin resistance and intestinal barrier outcomes, but the extraction reports only metabolite level changes, which the memo then labels 'directionally favorable' without justifying why altered metabolites constitute a favorable clinical signal. The bundle would benefit from either tighter PICO focus (e.g., quercetin in T2DM models) or an explicit cross-domain scoping framing that does not rely on a two-receipt 'favorable' count. Limitations and gaps are honestly stated. Recommend revise.

Panel metadata

Models: MiniMax-M3 + google/gemma-4-31b-it + mistralai/mistral-small-2603

Route: fallback_tiebreak_failed_conservative

Prompt: reviewer-v11-research-synthesis